Navigation Links
Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
Date:7/16/2008

SOUTH SAN FRANCISCO, Calif., July 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Tuesday, July 29, 2008 at 4:30 p.m. (Eastern Time) to discuss second quarter 2008 financial results. The call will be hosted by Mr. William D. Young, Chairman and CEO of Monogram.

To participate in the live teleconference, please call (877) 675-4748, or (719) 325-4848 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Following the live broadcast, a replay of the call will also be available beginning at 9:30 p.m. (Eastern Time) at (888) 203-1112, or (719) 457-0820 for international callers, until 11:59 p.m. (Eastern Time) on Tuesday, August 12, 2008. The replay passcode is 3249168. Access to live and archived audio of the conference call will be available by following the appropriate links at http://www.monogrambio.com and clicking on the Investor Relations link.

The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Contacts:

Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

amerriweather@monogrambio.com jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
2. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
3. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
4. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
5. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
7. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
8. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
9. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
10. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
11. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):